- Home
- CRVO vs RNAZ Comparison
CRVO vs RNAZ Comparison
Compare CRVO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | RNAZ |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 27.9M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRVO | RNAZ |
|---|---|---|
| Price | $3.24 | $1.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $15.40 | N/A |
| AVG Volume (30 Days) | ★ 207.2K | 45.5K |
| Earning Date | 11-09-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,006,510.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $525.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $1.52 |
| 52 Week High | $10.00 | $15.90 |
Technical Indicators
Market Signals| Indicator | CRVO | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 66.19 | 46.57 |
| Support Level | $2.44 | $1.83 |
| Resistance Level | $3.86 | $2.39 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 79.41 | 43.10 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.